PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will report third-quarter 2026 financial results on November 4, providing investors with an update on the financial performance and operations of the Plymouth Meeting-based pharmaceutical company focused on rare neurological diseases.
Harmony said it will release its results before U.S. financial markets open Wednesday, followed by a conference call and webcast at 8:30 a.m. Eastern Time.
The company develops and commercializes treatments for patients with rare neurological disorders, a specialized segment of the pharmaceutical market focused on conditions with limited treatment options.
Founded in 2017 by Paragon Biosciences LLC, Harmony is headquartered in Plymouth Meeting, Pennsylvania.
Investors can participate in the November 4 conference call by dialing 800-347-6865 domestically or 203-518-9757 internationally and using the passcode HRMYQ326.
The company recommends joining the call at least 10 minutes before its scheduled start.
A live webcast and subsequent replay will be available through Harmony’s investor relations website at https://ir.harmonybiosciences.com/.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.